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Non-calcified echogenic renal cortical nodules are commonly
detected with abdominal ultrasound (US). The majority of
these nodules represent benign angiomyolipomas (AMLs),
which are present in 0.3–2.1 % of the population at autopsy
[1]. The increased echogenicity (in the absence of calcifica-
tion) of renal AML is due to the presence of gross or mature
fat within the nodule [2]. Although renal AMLs are typically
markedly echogenic, echogenicity may vary depending upon
the relative proportion of fat, smoothmuscle and blood vessels
within the nodule [3, 4]. Renal cell carcinoma (RCC) is
traditionally considered to be less echogenic than renal corti-
cal parenchyma, although the echogenicity of RCC varies
with its size. Forman et al. [5] demonstrated that one-third of
RCCs less than 3 cm in size are as echogenic as “classic”
AML. In a recent meta-analysis, Farrelly et al. [6] demonstrat-
ed that nearly half of small RCCs are more echogenic than
renal cortical parenchyma and 11.5 % are as echogenic as
renal sinus fat. The increased echogenicity of small RCC is
attributed to cell arrangement with increased internal inter-
faces and the presence of internal degeneration or haemor-
rhage [7]. Nodule heterogeneity, intratumoural cysts and the
presence of a hypoechoic rim are specific sonographic find-
ings that favour echogenic RCC; while posterior acoustic
shadowing is a specific sonographic finding that favours
AML [6]. Although these differentiating sonographic findings
are specific, they lack the sensitivity required to discriminate
betweenAML and RCCwhen a small echogenic renal cortical
nodule is detected in everyday practice [6].
Given that small RCCs are commonly echogenic and may
mimic renal AMLs at US and that sonographic differentiating
features are insensitive, an imaging quandary occurs.
Confirmatory imaging with computed tomography (CT) is
generally accepted for larger lesions to detect the presence of
gross fat and confirm the presumed diagnosis of AML
(Fig. 1). For smaller lesions (<1 cm), recommendations vary
considerably and management is controversial (Fig. 1). Some
radiologists recommend no further follow-up imaging, con-
sidering them all small AMLs [2]. Sonographic follow-up is
prescribed by others, since small incidentally discovered renal
nodules grow slowly [8] and are associated with a low risk of
metastatic disease [9]. However, metastatic disease from small
RCC does occur [9] and both small RCC and AML can grow
slowly [2], making differentiation based on growth difficult. A
meta-analysis on the topic by Farelly et al. [6] concluded that,
based on the limited available literature, all incidentally de-
tected echogenic renal cortical nodules undergo confirmatory
imaging with CT. At our institution, we observe a variety of
practice patterns amongst radiologists, with many
recommending confirmatory CT for echogenic renal cortical
nodules measuring <1 cm in size.
The diagnosis of AML with CT is predicated on the ability
to demonstrate gross fat within the nodule, which is essentially
pathognomonic of AML; with only rare case reports of gross
fat within both papillary and clear cell RCC [10]. A represen-
tative region of interest (ROI) measurement within the nodule
measuring of fat density (less than −10 to −20 Hounsfield
units [HU]) is considered diagnostic of AML [11, 12]. For
larger nodules this is readily accomplished and an accurate
diagnosis of AML is achieved (Fig. 2). For smaller nodules
(<1 cm), particularly when the nodule is embedded within
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renal cortical parenchyma, this strategy repeatedly fails for
two principle reasons: (1) inability to accurately place a rep-
resentative ROI measurement due to lesion size and (2) vol-
ume averaging of imaging voxels containing an admixture of
renal parenchyma and lesional fat, which increases Hounsfield
unit density. This problem is worsened with larger voxel sizes;
for example, when using a thicker slice reconstruction inter-
val. If contrast-enhanced CT is performed, enhancement can-
not be accurately assessed for similar reasons. For the confir-
mation of gross fat, CT pixel mapping can increase the
diagnostic yield; with the requirement of four adjacent pixels
measuring less than −10 HU improving accuracy [11].
However, in these authors’ experience, CT pixel mapping is
also commonly non-diagnostic in small renal nodules due to
averaging of lesional fat and renal parenchyma and is gener-
ally under-utilised by interpreting radiologists. The next step
after a non-diagnostic CT varies, but could potentially result
in: (1) US or CT follow-up to confirm stability and assess for
growth, (2) contrast-enhanced CT (if this was not performed
from the outset) to assess for possible enhancement or (3)
Fig. 1 Diagnostic algorithms for incidentally detected echogenic renal
cortical nodules. a For nodules >1 cm in size, definitive characterisation
with CTor MRI to confirm the presence of gross fat and the diagnosis of
AML is widely accepted. b For nodules <1 cm in size, management
varies and is controversial. Options include: doing nothing, sonographic
follow-up to confirm stability in size or CT to confirm the presence of
gross fat and the diagnosis of AML. In our experience, the majority of
nodules <1 cm in size cannot be further characterised with CT, which can
lead to a variety of subsequent examinations including US or CT follow-
up, contrast-enhanced CT or MRI. c In our opinion, the radiologist
confronted with an incidental echogenic renal nodule measuring <1 cm
in size should consider either US follow-up to confirm stability, or if
definitive characterisation is required, chemical shift MRI and not CT
should be performed
Fig. 2 A 45-year-old woman with incidental echogenic renal cortical
nodule. Sagittal and transverse grey scale (a) and colour (b) images of the
left kidney depict a homogeneously hyperechoic nodule in the lower pole
(white arrows), which measures 10×12×14 mm in size. Axial contrast-
enhanced CT image (b) confirms the presence of a low-density nodule in
the lower pole of the left kidney that measures −42 HU, diagnostic of
gross fat and AML. Axial T1-weighted in-phase (IP) (c), opposed-phase
(OP) (d) and spectral fat suppressed (FS) (e) gradient recalled echo (GRE)
images demonstrate that the AML is isointense to retroperitoneal fat on IP
(solid black arrow in c) and demonstrates loss of with FS (open black
arrow in e) also diagnostic of gross or mature fat. Similarly, gross fat is
diagnosed on the OP (d) by noting “india ink” or “etching” artefact at the
margin of the nodule and the adjacent kidney (black arrow) and the
absence of etching artefact at the interface of the nodule with retroperito-
neal fat (dotted arrow)
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magnetic resonance imaging (MRI) (Fig. 1). The addition of
each subsequent imaging test adds undue imaging costs and
unnecessary morbidity for the patient.
The MRI diagnosis of AML also relies on the ability to
detect gross or macroscopic fat within the nodule. Gross fat
can be detected by comparison of T1 signal intensity with and
without the application of a variety of fat suppression tech-
niques, with the suppression of signal intensity within the
nodule diagnostic of gross fat [13]. Using this technique,
similar diagnostic accuracy can be achieved when compared
with CT for larger lesions. For the diagnosis of small (<1 cm)
lesions, fat suppressedMRI techniques (like CT) may also fail
to detect gross fat; with limitations related primarily to spatial
mis-registration from varying breath-holds between pulse
sequences.
The use of in-phase (IP) and opposed-phase (OP) chemical
shift imaging (CSI) can also be used to diagnose AML [12].
CSI exploits the different precessional frequencies of lipid and
water protons by imaging with gradient recalled echo (GRE)
at a pre-selected echo time (TE) when lipid/water protons are
either aligned (signal intensity is additive—referred to as IP)
or opposed (signal intensity cancels—referred to as OP) [14].
Imaging voxels located at the interface between water and fat
tissues contain an admixture of both lipid and water protons
which results in a signal loss within those imaging voxels
when imaged OP. This results in a dark line surrounding a
structure composed of primarily water protons (for example,
the kidney) that is surrounded by primarily fat (for example,
retroperitoneal fat) protons and is referred to as the “india ink”
or “etching” artefact [14]. A similar phenomenon occurs when
a structure composed of primarily fat protons is surrounded by
or embedded within a structure composed of primarily water
protons. The presence of etching or india ink artefact at the
interface of a renal cortical nodule within the kidney, or lack of
this artefact at the interface of this nodule with retroperitoneal
fat, is diagnostic of gross fat and therefore AML [12] (Fig. 2).
Within larger renal AML composed of varying amounts of fat,
smooth muscle and vessels; etching artefact within the nodule
Fig. 3 A 36-year-old man with incidental echogenic renal cortical nodule.
Sagittal and transverse grey scale and colour (a) images of the right kidney
depict a homogeneously hyperechoic nodule in the interpolar region (white
arrows) which measures 8×6×6 mm in size. Axial unenhanced CT image
(b) confirms the presence of a low-density nodule (open white arrow) with
an ROI measurement of −3 HU. Pixel mapping was not performed and a
follow-up CTwas recommended. Six-month follow-up contrast-enhanced
axial (c) CT image re-demonstrates the small renal cortical nodule (open
white arrow), which is not changed in size but remains indeterminate;MRI
was recommended. Axial T1-weighted IP, OP, and FS GRE images (left to
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right in d) reveal the renal nodule as a punctate focus of signal loss on OP
image only (white arrow). The lesion was again considered indeterminate
and follow-up was recommended. Axial T1-weighted IP, OP, and FS GRE
images (left to right in e) performed 3 years later confirm the diagnosis of
renal AMLwith persistent signal loss on the OP image (dotted arrow) and
loss of signal intensity now noted on FS (thick black arrow) comparedwith
IP (thin black arrow) T1-weighted images. In retrospect, the diagnosis was
apparent on initial MRI examination (d); signal loss on OP imaging in
uniformly echogenic nodules measuring <1 cm in size is confirmatory of
AML
is diagnostic of a gross fatty component [12]. In these authors’
experience, this imaging finding can reliably diagnose AML
of all sizes including tiny AML measuring only a few
millimetres (mm) in size, where CT and fat suppressed MRI
frequently fails (Figs. 3, 4). Whereas the averaging of lesional
fat and renal parenchyma within imaging voxels renders den-
sity measurements inaccurate, this limitation of CT forms the
basis of diagnosis with chemical shift MRI. An additional
benefit of chemical shift MRI compared with CT for the
characterisation of echogenic renal nodules is that it is non-
ionising, sparing radiation dose to this population of patients
who are being worked-up for incidentally detected imaging
findings. At our institution, a 10-min non-gadolinium en-
hanced protocol (designed for the characterisation of adrenal
nodules) can be used to confirm the diagnosis of AML in
<1 cm echogenic renal cortical nodules and consists of:
breath-hold axial and coronal T2-weighted single-shot fast
spin echo localiser sequences, breath-hold 2D and 3D IP and
OP CSI, and breath-hold axial 3D T1-weighted chemical fat
suppressed gradient recalled echo.
Important considerations for diagnosis of AML with CSI
include: nodule size, base voxel resolution, and the relative
amount of fat and water in each imaging voxel. If the nodule is
extremely small (<5 mm) and/or the base voxel resolution
(voxel size) is large, india ink artefact may completely obscure
the centre of the nodule such that only a spot of signal loss
(where the renal nodule is located) is appreciated on the OP
image (Fig. 4). It is essential not to confuse signal loss from
india ink artefact surrounding and obscuring a tiny lesion from
signal loss within a larger renal mass. Signal loss on OP
imaging from the presence of intracellular or microscopic lipid
within a renal mass is not specific for AML, known to occur in
clear cell RCC and recently been shown to occur in other renal
masses including papillary RCC [15, 16]. It has been previ-
ously suggested that intracellular lipid content is a feature of
minimal fat AML; however, this finding is not specific and,
given the overlap of other imaging features (such as homoge-
neous low T2 signal intensity) with papillary RCC, prospec-
tive diagnosis is not possible [16–18]. The US appearance of
minimal fat AML has not, to our knowledge, been described;
however, it can be concluded that should a small minimal fat
AML appear echogenic at US and undergo further character-
isation with CTorMRI without demonstration ofmacroscopic
fat, it should be treated as any other indeterminate solid renal
mass.
With CSI, the degree of signal loss on OP imaging is
dependent solely on the relative amounts of fat and water
within each imaging voxel. One can therefore expect a greater
Fig. 4 Schematic representation of renal AML diagnosis on OPMRI. In
larger lesions (a) the presence of india ink artefact around a nodule
embedded within the renal parenchyma is diagnostic of gross fat. If the
nodule is extremely small (b), india ink artefact may obscure the entire
lesion and the AML will appear only as a spot of signal loss within the
renal parenchyma. Similarly, if the base voxel resolution is too large (c),
india ink artefact may obscure the centre of the lesion so that the entire
lesion appears as a signal loss. A clinical example illustrates these
principles in a 38-year-old woman with tuberous sclerosis. A small
(5 mm) AML is present in the upper pole of the right kidney on axial
T1-weighted IP, OP, and FS GRE images (left to right in d). The AML is
depicted as a focus of increased T1 signal intensity on IP (black arrow)
with an etching artefact around its circumference on OP (open black
arrow) imaging and which loses signal intensity with chemical fat sup-
pression (white arrow). The lesion was only prospectively identified on
the opposed phase image and was indeterminate at CT (not shown). In the
same patient at a lower level (e), two tiny AML (<5 mm in size) in the
lower pole of the left kidney are only prospectively identified as areas of
signal loss on the opposed phase images (white arrows) but in retrospect
also demonstrate signal intensity loss with fat suppression (dotted
arrows). A similar phenomenon will be seen if a larger voxel size is used
(see Fig. 3)
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loss of signal (signal void) at the interface of large (Fig. 2) or
even small lesions with adequate base voxel resolution
(Fig. 4) and adjacent renal parenchyma where voxels contain
a relatively equal proportion of fat and water protons and
signal intensity cancels. If the nodule is extremely small or
with larger voxel sizes, the degree of signal loss may vary in
proportion to the relative amount of fat or water protons
contained within a particular imaging voxel. In our experi-
ence, even in the smallest of AML, the detection of a signal
loss on OP imaging is possible and the diagnosis of AML can
be established.
In conclusion, the incidental finding of an echogenic renal
cortical nodule is a commonly encountered clinical scenario
with an imaging differential diagnosis of renal AML or small
RCC. Differentiating sonographic features are specific but
lack sensitivity. Management strategies vary and are contro-
versial. Based on the best available evidence, CT has been
recommended for further characterisation of all echogenic
renal cortical nodules regardless of size. While this is gener-
ally widely accepted for larger nodules, whether CT is re-
quired for the characterisation of all lesions (including those
<1 cm) is uncertain due to a lack of available evidence. In the
opinion of these authors, if further imaging is requested or
performed for small (<1 cm) lesions, chemical shift MRI and
not CT is the preferred imaging test.
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